FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367835210> ?p ?o ?g. }

• W4367835210 endingPage "1051" @default.
• W4367835210 startingPage "1037" @default.
• W4367835210 abstract "Adagrasib is a recently US FDA-approved novel KRASG12C targeted therapy with clinical efficacy in patients with advanced, pretreated KRASG12C-mutated non-small-cell lung cancer. KRYSTAL-I reported an objective response rate of 42.9% with median duration of response of 8.5 months. Treatment-related adverse events were primarily gastrointestinal and occurred in 97.4% of patients, with grade 3+ treatment-related adverse events occurring in 44.8% of patients. This review details the preclinical and clinical data for adagrasib in the treatment of non-small-cell lung cancer. We also outline practical clinical administration guidelines for this novel therapy, including management of toxicities. Finally, we discuss the implications of resistance mechanisms, summarize other KRASG12C inhibitors currently in development and outline future directions for adagrasib-based combination therapies.Adagrasib is a new oral (taken by mouth) treatment option for patients with non-small-cell lung cancer (NSCLC) with KRASG12C mutations. KRAS is a gene that regulates signaling pathways, which are responsible for cell growth and division. A mutation in KRAS can cause cells to multiply and cause cancer. Clinical trials have shown that adagrasib causes cancer reduction or resolution in 42.9% of people with NSCLC with KRASG12C mutations who receive the drug. Side effects of adagrasib are primarily gastrointestinal (nausea, vomiting, diarrhea). This review outlines guidelines for the management of side effects. New studies are looking at how adagrasib can be safely combined with other therapies to better treat NSCLC with KRASG12C mutations." @default.
• W4367835210 created "2023-05-04" @default.
• W4367835210 creator A5003413809 @default.
• W4367835210 creator A5012455959 @default.
• W4367835210 creator A5044613951 @default.
• W4367835210 creator A5057631025 @default.
• W4367835210 date "2023-05-01" @default.
• W4367835210 modified "2023-10-02" @default.
• W4367835210 title "Adagrasib: a novel inhibitor for <i>KRAS^G12C</i>-mutated non-small-cell lung cancer" @default.
• W4367835210 cites W1497255210 @default.
• W4367835210 cites W1964497970 @default.
• W4367835210 cites W1971102429 @default.
• W4367835210 cites W2024839004 @default.
• W4367835210 cites W2082616626 @default.
• W4367835210 cites W2098272135 @default.
• W4367835210 cites W2099536948 @default.
• W4367835210 cites W2099680642 @default.
• W4367835210 cites W2107879261 @default.
• W4367835210 cites W2128339707 @default.
• W4367835210 cites W2129429534 @default.
• W4367835210 cites W2145411470 @default.
• W4367835210 cites W2146926552 @default.
• W4367835210 cites W2166749501 @default.
• W4367835210 cites W2233032895 @default.
• W4367835210 cites W2300615341 @default.
• W4367835210 cites W2414938939 @default.
• W4367835210 cites W2501247313 @default.
• W4367835210 cites W2561459036 @default.
• W4367835210 cites W2590660318 @default.
• W4367835210 cites W2766371263 @default.
• W4367835210 cites W2769635882 @default.
• W4367835210 cites W2785187242 @default.
• W4367835210 cites W2792521137 @default.
• W4367835210 cites W2804812017 @default.
• W4367835210 cites W2890164144 @default.
• W4367835210 cites W2906754611 @default.
• W4367835210 cites W2913235593 @default.
• W4367835210 cites W2921771746 @default.
• W4367835210 cites W2967210753 @default.
• W4367835210 cites W2982602983 @default.
• W4367835210 cites W2982649277 @default.
• W4367835210 cites W3001129149 @default.
• W4367835210 cites W3004931546 @default.
• W4367835210 cites W3007112359 @default.
• W4367835210 cites W3014882016 @default.
• W4367835210 cites W3016044799 @default.
• W4367835210 cites W3023379891 @default.
• W4367835210 cites W3036720502 @default.
• W4367835210 cites W3040830058 @default.
• W4367835210 cites W3041824636 @default.
• W4367835210 cites W3083408034 @default.
• W4367835210 cites W3085717162 @default.
• W4367835210 cites W3092240262 @default.
• W4367835210 cites W3092968030 @default.
• W4367835210 cites W3097340813 @default.
• W4367835210 cites W3110833960 @default.
• W4367835210 cites W3111812619 @default.
• W4367835210 cites W3119111229 @default.
• W4367835210 cites W3120568861 @default.
• W4367835210 cites W3124985277 @default.
• W4367835210 cites W3127560436 @default.
• W4367835210 cites W3134146062 @default.
• W4367835210 cites W3136047951 @default.
• W4367835210 cites W3136351248 @default.
• W4367835210 cites W3142010099 @default.
• W4367835210 cites W3145766479 @default.
• W4367835210 cites W3152750912 @default.
• W4367835210 cites W3157480760 @default.
• W4367835210 cites W3163195272 @default.
• W4367835210 cites W3171491383 @default.
• W4367835210 cites W3171675220 @default.
• W4367835210 cites W3172081492 @default.
• W4367835210 cites W3172183878 @default.
• W4367835210 cites W3181973044 @default.
• W4367835210 cites W3192028440 @default.
• W4367835210 cites W3203232566 @default.
• W4367835210 cites W3212888956 @default.
• W4367835210 cites W3214844045 @default.
• W4367835210 cites W3216088237 @default.
• W4367835210 cites W4205186273 @default.
• W4367835210 cites W4206141972 @default.
• W4367835210 cites W4213177438 @default.
• W4367835210 cites W4214569871 @default.
• W4367835210 cites W4220722404 @default.
• W4367835210 cites W4220960854 @default.
• W4367835210 cites W4223491316 @default.
• W4367835210 cites W4225529913 @default.
• W4367835210 cites W4225576930 @default.
• W4367835210 cites W4226382697 @default.
• W4367835210 cites W4280529545 @default.
• W4367835210 cites W4281650778 @default.
• W4367835210 cites W4285494293 @default.
• W4367835210 cites W4285503346 @default.
• W4367835210 cites W4285987606 @default.
• W4367835210 cites W4293083660 @default.
• W4367835210 cites W4294943816 @default.
• W4367835210 cites W4296768674 @default.
• W4367835210 cites W4296768824 @default.

• next